Proactively Addressing Access and Reimbursement Challenges for ALS Therapeutics

Implications for clinical development

Michael Murphy, MD, PhD

On the quest to bring treatments to patients, it can be easy to forget it requires much more than just regulatory approval. There’s payer policies, cost to patients and caregivers…and it’s especially important to those stakeholders that you’ve captured the data necessary to show demonstrated clinical benefit. Take a disease with high rates of morbidity and mortality like ALS, and access variables become even more complicated.

How can you strategically navigate this complex environment and capture the data relevant to the many distinct stakeholders? Find out how: 

Your form has been successfully submitted! Click the button below to access.
READ MORE
Michael Murphy, MD, PhD
MEET THE AUTHOR

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer
LEARN MORE